Liver Disease and Osteoporosis

Abstract

Metabolic bone disease (osteodystrophy) is an important complication of patients with chronic liver disease; its etiology is complex and multifactorial. Osteodystrophy is manifested as osteopenia/osteoporosis. Osteoporosis can predispose patients to bone fractures, increasing morbidity and mortality, especially after liver transplantation. Early evaluation, screening, and treatment of bone disorders in patients with liver disease are essential to minimize fracture risk and to improve clinical outcome and quality of life.

Get full access to this article

View all access options for this article.

References

Bringhurst R, Demay M, Kronenberg H. Hormones and disorders of mineral metabolism In: Larsen R, Kronenberg H, Melmed S, Polonsky K, eds. Williams Textbook of Endocrinology, 10th ed. St. Louis, MO: W.B. Saunders Company; 2003:1317– 1320.

Brown SA. Osteoporosis. Med Clin North Am. 2003 ;87:1039– 1063.

Riggs BL, Melton LJ 3rd. Involutional osteoporosis. N Engl J Med. 1986;314:1676– 1679.

Barrett-Connor E, Siris ES, Wehren LE, et al. Osteoporosis and fracture risk in women of different ethnic groups. J Bone Miner Res. 2005;20:185– 194.

Rouillard S, Lane NE. Hepatic osteodystrophy. Hepatology. 2001;33 : 301–307.

Leslie WD, Bernstein CN, Leboff MS, American Gastroenterological Association Clinical Practice Committee. AGA technical review on osteoporosis in hepatic disorders. Gastroenterology. 2003 ;125:941– 966.

Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison of new biochemical markers of bone turnover in late post-menopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab. 1994;79:1693– 1700.

Sokhi RP, Anantharaju A, Kondaveeti R, Creech SD, Islam KK, Van Thiel DH. Bone mineral density among cirrhotic patients awaiting liver transplantation. Liver Transpl. 2004 ;10:648– 653.

Ninkovic M, Love SA, Tom B, Alexander GJ, Compston JE. High prevalence of osteoporosis in patients with chronic liver disease prior to liver transplantation. Calcif Tissue Int. 2001 ;69:321– 326.

10.

Gallego-Rojo FJ, Gonzalez-Calvin JL, Munoz-Torres M, Mundi JL, Fernandez-Perez R, Rodrigo-Moreno D. Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. Hepatology. 1998 ;28:695– 699.

11.

Collier JD, Ninkovic M, Compston JE. Guidelines on the management of osteoporosis associated with chronic liver disease. Gut. 2002;50(suppl 1): i1–i9.

12.

Hay JE, Guichelaar MM. Evaluation and management of osteoporosis in liver disease. Clin Liver Dis. 2005 ;9:747– 766.

13.

Nieves JW. Osteoporosis: the role of micronutrients. Am J Clin Nutr. 2005;81:1232S– 1239S.

14.

Hay JE. Bone disease in cholestatic liver disease. Gastroenterology. 1995 ;108:276– 283.

15.

Compston JE. Hepatic osteodystrophy: vitamin D metabolism in patients with liver disease. Gut. 1986 ;27:1073– 1090.

16.

Ralston SH. Genetic control of susceptibility to osteoporosis. J Clin Endocrinol Metab. 2002 ;87:2460– 2466.

17.

Halmos B, Szalay F, Cserniczky T, et al. Association of primary biliary cirrhosis with vitamin D receptor BsmI genotype polymorphism in a Hungarian population. Dig Dis Sci. 2000 ;45:1091– 1095.

18.

Kaneki M. Vitamin K2 as a protector of bone health and beyond. Clin Calcium. 2005 ;15:605– 610.

19.

Okano T. Vitamin D, K and bone mineral density. Clin Calcium. 2005;15:1489– 1494.

20.

Iinuma N. Vitamin K2 (menatetrenone) and bone quality. Clin Calcium. 2005 ;15:1034– 1039.

21.

Menon KV. Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. J Hepatol. 2001 ;35:316– 323.

22.

Corazza GR, Trevisani F, Di Stefano M, et al. Early increase of bone resorption in patients with liver cirrhosis secondary to viral hepatitis. Dig Dis Sci. 2000 ;45:1392– 1399.

23.

Toth M, Tulassay Z. Glucocorticoid-induced osteoporosis. Orv Hetil. 2000 ;141:219– 223.

24.

Boling EP. Secondary osteoporosis: underlying disease and the risk for glucocorticoid-induced osteoporosis. Clin Ther. 2004 ;26:1– 14.

25.

Menon K, Angulo P, Weston S, Dickson ER, Lindor KD. Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. J Hepatol. 2001 ;35:316– 332.

26.

Ormarsdottir S, Ljunggren O, Mallmin H, Brahm H, Loof L. Low body mass index and use of corticosteroids, but not cholestasis, are risk factors for osteoporosis in patients with chronic liver disease. J Hepatol. 1999;31:84– 90.

27.

Taylor AK, Lueken SA, Libanati C, Baylink DJ. Biochemical markers of bone turnover for the clinical assessment of bone metabolism. Rheum Dis Clin North Am. 1994 ;20:589– 607.

28.

Hammett-Stabler CA. The use of biochemical markers in osteoporosis. Clin Lab Med. 2004 ;24:175– 197.

29.

Julian BA, Benfield M, Quarles LD. Bone loss after organ transplantation. Transplant Rev. 1993 ;7:82– 95.

30.

Millonig G, Graziadei IW, Eichler D, et al. Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study. Liver Transpl. 2005;11:960– 966.

31.

Hay JE. Osteoporosis in liver diseases and after liver transplantation. J Hepatol. 2003 ;38:856– 865.

32.

Compston J. Osteoporosis associated with gastrointestinal diseases. Eur J Gastroenterol Hepatol. 2003 ;15:841– 843.

33.

NIH Consensus conference. Optimal calcium intake: NIH Consensus Development Panel on Optimal Calcium Intake. JAMA. 1994 ;272:1942– 1948.

34.

Chesnut CH 3rd, Silverman S, Andriano K, et al. Randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study: PROOF Study Group. Am J Med. 2000 ;109:267– 276.

35.

Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in post-menopausal osteoporosis: the Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med. 1995 ;333:1437– 1443.

36.

Guanabens N, Pares A, del Rio L, et al. Sodium fluoride prevents bone loss in primary biliary cirrhosis. J Hepatol. 1992 ;15:345– 349.

37.

Neer RM, Amaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in post-menopausal women with osteoporosis. N Engl J Med. 2001 ;344:1434– 1441.

38.

Holick MF. PTH (1–34): a novel anabolic drug for the treatment of osteoporosis. South Med J. 2005 ;98:1114– 1117.

39.

Levy C, Harnois DM, Angulo P, Jorgensen R, Lindor KD. Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis: results of a pilot study. Liver Int. 2005 ;25:117– 121.

40.

Shimon I, Eshed V, Doolman R, Sela BA, Karasik A, Vered I. Alendronate for osteoporosis in men with androgen-repleted hypogonadism. Osteoporos Int. 2005 ;16:1591– 1596.